SIDP is pleased to join over 30 organizations in expressing support for congress to approve the Re-Valuing Antimicrobial Products (REVAMP) Act. This act aims to de-link incentives for the development of priority antimicrobials from the bulk number of sales or amount administered of those agents. In short, the REVAMP Act would develop a process where a company who brings a new priority antimicrobial to market may transfer up to 12 months of exclusivity to another product in order to provide financial incentive for antimicrobial development. The REVAMP Act would also require the sponsor to ensure proper stewardship of the novel antimicrobial agent as part of the agreement. SIDP applauds this novel approach to ensure both the continued development of new antimicrobials for life threatening drug-resistant infections as well as responsible stewardship of these agents.
Read the statement of support here.
Click here to read either a summary or the full REVAMP act.